Results 71 to 80 of about 9,015 (261)

Impact of Nirsevimab on RSV and Non‐RSV Severe Respiratory Infections in Hospitalized Infants

Influenza and Other Respiratory Viruses, Volume 19, Issue 5, May 2025.
ABSTRACT Background Nirsevimab, a monoclonal antibody providing passive immunity against RSV infections in infants, was introduced in Spain in October 2023 for children under 6 months and those born during the epidemic season. This study aimed to compare the clinical and virological characteristics of respiratory infections in hospitalized infants ...
María Luz García‐García, Patricia Alonso‐López, Sonia Alcolea, M. Arroyas, Francisco Pozo, Inmaculada Casas, Maria Iglesias‐Caballero, Rocío Sánchez‐León, Jara Hurtado‐Gallego, Cristina Calvo   +9 more
wiley   +1 more source

Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis [PDF]

Pediatric Pulmonology, 2012
AbstractBackgroundEvidence on the effectiveness of respiratory syncytial virus (RSV) immunoprophylaxis with palivizumab in children with cystic fibrosis (CF) is lacking.MethodsWe utilized Medicaid Extract files from 27 states from 1999 to 2006 linked to the National Cystic Fibrosis Registry to establish a cohort of children 0–2 years with CF diagnosis.
Dandan Xu, Pamela M. Schuler, Efe Eworuke, Almut G. Winterstein   +3 more
openaire   +3 more sources

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Human Vaccines & Immunotherapeutics, 2023
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended ...
Elizabeth R. Packnett, Isabelle H. Winer, Abiola Oladapo, Matthew Wojdyla   +3 more
doaj   +1 more source

Intranasal Inoculation of Cationic Crosslinked Carbon Dots‐Adjuvanted Respiratory Syncytial Virus F Subunit Vaccine Elicits Mucosal and Systemic Humoral and Cellular Immunity

MedComm, Volume 6, Issue 4, April 2025.
We prepared a CCD‐adjuvanted preF vaccine for intranasal delivery against RSV infection. Three‐dose intranasal administration of this vaccine induced long‐lasting humoral and cellular immunity against RSV F protein at both local sites and systemic immune organs.
Hong Lei, Aqu Alu, Jingyun Yang, Cai He, Jie Shi, Weiqi Hong, Dandan Peng, Yu Zhang, Jian Liu, Furong Qin, Xiya Huang, Chunjun Ye, Lijiao Pei, Xuemei He, Hong Yan, Guangwen Lu, Xiangrong Song, Xiawei Wei, Yuquan Wei   +18 more
wiley   +1 more source

Palivizumab: Four Seasons in Russia

Annals of the Russian academy of medical sciences, 2014
In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically ...
Baranov A.A., Ivanov D.O., Alyamovskaya G.A., Amirova V.R., Antonyuk I.V., Asmolova G.A., Belyaeva I.A., Bokeriya E.L., Bryukhanova O.A., Vinogradova I.V., Vlasova E.V., Galustyan A.N., Gafarova G.V., Gorev V.V., Davydova I.V., Degtyarev D.N., Degtyareva E.A., Dolgikh V.V., Donin I.M., Zakharova N.I., Zernova L.Yu., Zimina E.P., Zuev V.V., Keshishyan E.S., Kovalev I.A., Koltunov I.E., Korsunskii A.A., Krivoshchekov E.V., Krsheminskaya I.V., Kuznetsova S.N., Lyubimenko V.A., Namazova-Baranova L.S., Nesterenko E.V., Nikolaev S.V., Ovsyannikov D.Yu., Pavlova T.I., Potapova M.V., Rychkova L.V., Safarov A.A., Safina A.I., Skachkova M.A., Soldatova I.G., Turti T.V., Filatova N.A., Shakirova R.M., Yanulevich O.S.   +45 more
openaire   +5 more sources

Estimate of Effectiveness of Palivizumab in the Prevention of Respiratory Syncytial Virus-Related Hospitalizations in a Cohort of Premature Children [PDF]

, 2006
As recomendações da Secção de Neonatologia da Sociedade Portuguesa de Pediatria (SNN-SPP) prevêem a profilaxia medicamentosa da infecção por vírus sincicial respiratório (VSR) com palivizumab em idades gestacionais (IG)inferiores a 30 semanas.
Costa, C, Dias Alves, A, Franco, J, Jorge, A, Queiroz, AM, Virella, D   +5 more
core  

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein [PDF]

, 2014
Infections with human respiratory syncytial virus (HRSV) occur globally in all age groups and can have devastating consequences in young infants. We demonstrate that a vaccine based on the extracellular domain (SHe) of the small hydrophobic (SH) protein ...
Bert Schepens, Brian Gilbert, Cherrie AH, Connors M, Glezen WP, Kenny Roose, Koen Sedeyn, Liesbeth Vande Ginste, Lieselot Houspie, Marc Van Ranst, Michael Schotsaert, Mills JT, Nicholas JA, Nico Rooijen, Olmsted RA, Pedro Piedra, Sarah De Baets, Ventre K, Walter Fiers, Whitehead SS, Xavier Saelens   +20 more
core   +3 more sources

Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus [PDF]

, 2006
The mechanism by which respiratory syncytial virus (RSV) suppresses T-cell proliferation to itself and other antigens is poorly understood. We used monocyte-derived dendritic cells (MDDC) and CD4 T cells and measured [(3)H]thymidine incorporation to ...
Alston, Marc A., Beeler, Judy A., Chi, Bo, Collins, Peter L., Dickensheets, Harold L., Donnelly, Raymond P., Dumoutier, Laure, Huang, Jiaying, Kotenko, Sergei V., Luongo, Cindy, Rabin, Ronald L., Renauld, Jean-Christophe, Roederer, Mario, Spann, Kirsten M.   +13 more
core   +2 more sources

Model evaluation of target product profiles of an infant vaccine against respiratory syncytial virus (RSV) in a developed country setting [PDF]

, 2020
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in children worldwide and is a significant cause of hospital admissions in young children in England.
Kinyanjui, Timothy, Nokes, D. James, Pan-Ngum, Wirichada, Saralamba, Sompob, Taylor, Sylvia, White, Lisa J.   +5 more
core   +1 more source

PIN69 Cost Utility Analysis of 13-Valent Pneumococcal Conjugate Vaccine in Malaysia [PDF]

, 2011
Farrando Sicilia, Jordi; Lecea, Ignasi de; Fuente Fuente, Carlos; Ribas Seix, Anna; Masana Padrós, Judit; Delgado, José ...
Wu, D.B.C., Lee, K.K., Lee, V.W., Hong, L.W., Roberts, C.S.   +4 more
core   +1 more source